Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 6/2004

01.06.2004 | Review

Coagulation in sepsis

verfasst von: André Amaral, Steven M. Opal, Jean-Louis Vincent

Erschienen in: Intensive Care Medicine | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Coagulation abnormalities, ranging from a simple fall in platelet count to full-blown disseminated intravascular coagulation, are a common occurrence in critically ill patients and have been associated with increased mortality. In sepsis, activation of the extrinsic coagulation pathway by tissue factor induces increased coagulation, and simultaneous depression of the inhibitory mechanisms of coagulation, and suppression of the fibrinolytic system results in a procoagulant state that may lead to the formation of microvascular thrombi disturbing organ microcirculation and promoting the development of organ dysfunction. Many inflammatory mediators are involved in the activation of coagulation, but many coagulation proteins are themselves actively involved in the inflammatory process. In this article, we explore the complex relationship between inflammation and coagulation and how improved understanding of this interaction has led to the development of new therapeutic agents for patients with severe sepsis.
Literatur
1.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMed
2.
Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMed
2a.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Swoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Pekelseln C, De Deyner C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobis J, Poole L, Stolzenbach JC, Creasy AA, OPTIMIST Trial Study Group (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290:238–247CrossRefPubMed
3.
Davie EW, Ratnoff OD (1964) Waterfall sequence for intrinsic blood clotting. Science 145:1310–1312
4.
MacFarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 202:498–499
5.
Hoffman M, Monroe DM III (2001) A cell-based model of hemostasis. Thromb Haemost 85:958–965PubMed
6.
van’t Veer C, Mann KG (1997) Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin- III, and heparin cofactor-II. J Biol Chem 272:4367–4377CrossRefPubMed
7.
Osterud B (1998) Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 9[Suppl 1]:S9–14
8.
Osterud B, Rapaport SI (1977) Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 74:5260–5264PubMed
9.
Morrissey JH, Macik BG, Neuenschwander PF, Comp PC (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734–744PubMed
10.
Nemerson Y, Repke D (1985) Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 40:351–358CrossRefPubMed
11.
Morrissey JH (2001) Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 86:66–74PubMed
12.
Nakagaki T, Foster DC, Berkner KL, Kisiel W (1991) Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent autoactivation of human coagulation factor VII. Biochemistry 30:10819–10824PubMed
13.
Neuenschwander PF, Fiore MM, Morrissey JH (1993) Factor VII autoactivation proceeds via interaction of distinct protease- cofactor and zymogen-cofactor complexes. Implications of a two- dimensional enzyme kinetic mechanism. J Biol Chem 268:21489–21492PubMed
14.
Diaz-Ricart M, Estebanell E, Lozano M, Aznar-Salatti J, White JG, Ordinas A, Escolar G (2000) Thrombin facilitates primary platelet adhesion onto vascular surfaces in the absence of plasma adhesive proteins: studies under flow conditions. Haematologica 85:280–288PubMed
15.
Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR (2001) Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 413:74–78CrossRefPubMed
16.
Monroe DM, Hoffman M, Roberts HR (1996) Transmission of a procoagulant signal from tissue factor-bearing cell to platelets. Blood Coagul Fibrinolysis 7:459–464PubMed
17.
Romp KG, Monroe DM, Hoffman M (1993) Platelets contain releasable coagulation factor IX antigen. Blood Coagul Fibrinolysis 4:905–910PubMed
18.
Mosesson MW (1992) The roles of fibrinogen and fibrin in hemostasis and thrombosis. Semin Hematol 29:177–188PubMed
19.
Schwartz ML, Pizzo SV, Hill RL, McKee PA (1971) The subunit structures of human plasma and platelet factor XIII (fibrin- stabilizing factor). J Biol Chem 246:5851–5854PubMed
20.
Redlitz A, Tan AK, Eaton DL, Plow EF (1995) Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 96:2534–2538PubMed
21.
Pizzo SV, Schwartz ML, Hill RL, McKee PA (1973) The effect of plasmin on the subunit structure of human fibrin. J Biol Chem 248:4574–4583PubMed
22.
Weitz JI, Stewart RJ, Fredenburgh JC (1999) Mechanism of action of plasminogen activators. Thromb Haemost 82:974–982PubMed
23.
Idell S (2002) Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 30:S274–S280CrossRefPubMed
24.
Broze GJ Jr (1992) Why do hemophiliacs bleed? Hosp Pract (Off Ed) 27:71–82,85
25.
Sanders NL, Bajaj SP, Zivelin A, Rapaport SI (1985) Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 66:204–212PubMed
26.
Blajchman MA, Austin RC, Fernandez-Rachubinski F, Sheffield WP (1992) Molecular basis of inherited human antithrombin deficiency. Blood 80:2159–2171PubMed
27.
Marciniak E (1973) Factor-Xa inactivation by antithrombin. 3. Evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 24:391–400PubMed
28.
Esmon CT (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743–4746PubMed
29.
Kisiel W (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by alpha-thrombin. J Clin Invest 64:761–769PubMed
30.
Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT (1996) The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci U S A 93:10212–10216CrossRefPubMed
31.
Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH (1986) Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 68:1218–1223PubMed
32.
Esmon CT (2000) Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 95:1113–1116PubMed
33.
Esmon CT (2001) Role of coagulation inhibitors in inflammation. Thromb Haemost 86:51–56PubMed
34.
Schaub RG, Simmons CA, Koets MH, Romano PJ, Stewart GJ (1984) Early events in the formation of a venous thrombus following local trauma and stasis. Lab Invest 51:218–224PubMed
35.
Yang J, Furie BC, Furie B (1999) The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 81:1–7
36.
Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW (1994) P-selectin and platelet-activating factor mediate initial endotoxin- induced neutropenia. J Exp Med 179:329–334PubMed
37.
Lim YC, Snapp K, Kansas GS, Camphausen R, Ding H, Luscinskas FW (1998) Important contributions of P-selectin glycoprotein ligand-1-mediated secondary capture to human monocyte adhesion to P-selectin, E-selectin, and TNF-alpha-activated endothelium under flow in vitro. J Immunol 161:2501–2508PubMed
38.
Ramasamy S, Lipke DW, McClain CJ, Hennig B (1995) Tumor necrosis factor reduces proteoglycan synthesis in cultured endothelial cells. J Cell Physiol 162:119–126PubMed
39.
Klein NJ, Shennan GI, Heyderman RS, Levin M (1992) Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 102[Pt 4]:821–832
40.
Conway EM, Rosenberg RD (1988) Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8:5588–5592PubMed
41.
Murugesan G, Rani MR, Ransohoff RM, Marchant RE, Kottke-Marchant K (2000) Endothelial cell expression of monocyte chemotactic protein-1, tissue factor, and thrombomodulin on hydrophilic plasma polymers. J Biomed Mater Res 49:396–408CrossRefPubMed
42.
Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU (1987) Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 79:124–130PubMed
43.
Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB (1993) Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91:2850–2856PubMed
44.
de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, Van Deventer SJ, van der PT (2000) Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 95:1124–1129PubMed
45.
de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, Van Deventer SJ, van der PT (2001) Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis 183:1815–1818CrossRefPubMed
46.
Opal SM, Palardy JE, Parejo NA, Creasey AA (2001) The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 29:13–17
47.
Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 163:1404–1411PubMed
48.
Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K (1999) Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93:157–164PubMed
49.
Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P (1997) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96:2302–2310PubMed
50.
Uchiba M, Okajima K (1997) Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III. Semin Thromb Hemost 23:583–590PubMed
51.
Totzke G, Schobersberger W, Schloesser M, Czechowski M, Hoffmann G (2001) Effects of antithrombin III on tumor necrosis factor-alpha and interleukin-1beta synthesis in vascular smooth muscle cells. J Interferon Cytokine Res 21:1063–1069CrossRefPubMed
52.
Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW (1994) Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester. J Immunol 153:3664–3672PubMed
53.
Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, Nakano K, Utoh J, Okabe H, Kitamura N (2000) Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 232:272–280CrossRefPubMed
54.
Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, Takatsuki K (1997) Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272:L197–L202PubMed
55.
Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, Esmon CT (1991) C4b-binding protein exacerbates the host response to Escherichia coli. Blood 78:357–363PubMed
56.
Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT (2000) The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95:1680–1686PubMed
57.
White B, Schmidt M, Murphy C, Livingstone W, O’Toole D, Lawler M, O’Neill L, Kelleher D, Schwarz HP, Smith OP (2000) Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 110:130–134CrossRefPubMed
58.
Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW (2001) Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 276:11199–11203CrossRefPubMed
59.
Esmon CT (2001) Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 29:S48–S51
60.
Rocha E, Paramo JA, Montes R, Panizo C (1998) Acute generalized, widespread bleeding. Diagnosis and management. Haematologica 83:1024–1037PubMed
61.
Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005–2009
62.
Hesselvik FJ, Blomback M, Brodin B, Maller R (1989) Coagulation, fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17:724–733PubMed
63.
McGee MP, Foster S, Wang X (1994) Simultaneous expression of tissue factor and tissue factor pathway inhibitor by human monocytes. A potential mechanism for localized control of blood coagulation. J Exp Med 179:1847–1854PubMed
64.
Rana SV, Reimers HJ, Pathikonda MS, Bajaj SP (1988) Expression of tissue factor and factor VIIa/tissue factor inhibitor activity in endotoxin or phorbol ester stimulated U937 monocyte-like cells. Blood 71:259–262PubMed
65.
Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88:881–886PubMed
66.
Hesselvik JF, Malm J, Dahlback B, Blomback M (1991) Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 65:126–129PubMed
67.
Leithauser B, Matthias FR, Nicolai U, Voss R (1996) Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation? Intensive Care Med 22:631–636PubMed
68.
Philippe J, Offner F, Declerck PJ, Leroux-Roels G, Vogelaers D, Baele G, Collen D (1991) Fibrinolysis and coagulation in patients with infectious disease and sepsis. Thromb Haemost 65:291–295PubMed
69.
Martinez MA, Pena JM, Fernandez A, Jimenez M, Juarez S, Madero R, Vazquez JJ (1999) Time course and prognostic significance of hemostatic changes in sepsis: relation to tumor necrosis factor-alpha. Crit Care Med 27:1303–1308PubMed
70.
Mavrommatis AC, Theodoridis T, Economou M, Kotanidou A, El Ali M, Christopoulou-Kokkinou V, Zakynthinos SG (2001) Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock. Intensive Care Med 27:1853–1859CrossRefPubMed
71.
Opal SM (2000) Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 28:S34–S37CrossRefPubMed
72.
Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, Van Deventer SJ, ten Cate JW (1995) Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 73:15–20PubMed
73.
Leclerc F, Hazelzet J, Jude B, Hofhuis W, Hue V, Martinot A, Van der Voort E (1992) Protein C and S deficiency in severe infectious purpura of children: a collaborative study of 40 cases. Intensive Care Med 18:202–205PubMed
74.
Lorente JA, Garcia-Frade LJ, Landin L, De Pablo R, Torrado C, Renes E, Garcia-Avello A (1993) Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 103:1536–1542PubMed
75.
Gando S, Kameue T, Nanzaki S, Nakanishi Y (1995) Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 80:519–526CrossRefPubMed
76.
Ishii H, Uchiyama H, Kazama M (1991) Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 65:618–623PubMed
77.
Bajzar L, Nesheim ME, Tracy PB (1996) The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88:2093–2100PubMed
78.
Mosnier LO, Meijers JC, Bouma BN (2001) Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 85:5–11PubMed
79.
Gando S, Nanzaki S, Sasaki S, Aoi K, Kemmotsu O (1998) Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock. Crit Care Med 26:2005–2009
80.
Mavromatis BH, Kessler CM (2001) D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol 54:664–668PubMed
81.
Dofferhoff AS, Bom VJ, de Vries Hospers HG, van Ingen J, v.d.Meer J, Hazenberg BP, Mulder PO, Weits J (1992) Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 20:185–192PubMed
82.
Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H (2001) Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 104:1–6CrossRefPubMed
83.
Amitrano L, Guardascione MA, Brancaccio V, Balzano A (2002) Coagulation disorders in liver disease. Semin Liver Dis 22:83–96CrossRefPubMed
84.
ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma PH (2001) Microvascular coagulopathy and disseminated intravascular coagulation. Crit Care Med 29:S95–S97CrossRefPubMed
85.
van ‘t Veer C, Golden NJ, Kalafatis M, Mann KG (1997) Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J Biol Chem 272:7983–7994CrossRefPubMed
86.
DePalo V, Kessler C, Opal SM (2001) Success or failure in phase III sepsis trials: comparisons between the Drotrecogin alfa (activated) and antithrombin III clinical trials. Adv Sepsis 1:114–124
87.
Kessler CM, Tang Z, Jacobs HM, Szymanski LM (1997) The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 89:4393–4401PubMed
Metadaten
Titel
Coagulation in sepsis
verfasst von
André Amaral
Steven M. Opal
Jean-Louis Vincent
Publikationsdatum
01.06.2004
Verlag
Springer-Verlag
Erschienen in
Intensive Care Medicine / Ausgabe 6/2004
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-004-2291-8

Weitere Artikel der Ausgabe 6/2004

Intensive Care Medicine 6/2004 Zur Ausgabe

Original

Can the impact of bed closure in intensive care units be reliably monitored?

Experimental

Monitoring of respiratory variations of aortic blood flow velocity using esophageal Doppler

Brief Report

Analysis of terminal events in 109 successive deaths in a Belgian intensive care unit

Brief Report

The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome

Brief Report

Use of percutaneous tracheostomy in intensive care units in Spain. Results of a national survey

Review

Year in review in Intensive Care Medicine—2003

Neu im Fachgebiet AINS

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise